Deerfield Management Company, L.P. (Series C) Adma Biologics, Inc. Transaction History
Deerfield Management Company, L.P. (Series C)
- $5.38 Billion
- Q3 2024
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Adma Biologics, Inc. stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 47,016 shares of ADMA stock, worth $872,616. This represents 0.02% of its overall portfolio holdings.
Number of Shares
47,016
Previous 59,220
20.61%
Holding current value
$872,616
Previous $662,000
41.84%
% of portfolio
0.02%
Previous 0.01%
Shares
4 transactions
Others Institutions Holding ADMA
# of Institutions
318Shares Held
184MCall Options Held
917KPut Options Held
91.6K-
Black Rock Inc. New York, NY18.6MShares$346 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA18.1MShares$336 Million0.01% of portfolio
-
State Street Corp Boston, MA13MShares$241 Million0.01% of portfolio
-
Invesco Ltd. Atlanta, GA12.6MShares$234 Million0.05% of portfolio
-
Morgan Stanley New York, NY8.6MShares$160 Million0.01% of portfolio
About ADMA BIOLOGICS, INC.
- Ticker ADMA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 196,356,992
- Market Cap $3.64B
- Description
- ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primar...